Stop paying your staff to make repetitive reports
How Much Time Are You Wasting on Manual, Repetitive Tasks? Stop wasting time on repetitive reports: Contact us Are your […]
Stop paying your staff to make repetitive reports Read Post »
Insights
The Global Biosimilar Regulatory Playbook: FDA, EMA, IP Valuation, and the $136 Billion Market Restructuring
The biosimilar market is not a niche concern for generic drug manufacturers. It is the central mechanism by which payors,
Pharmaceutical Procurement: The Complete Intelligence Guide for IP Teams, R&D Leads, and Institutional Investors
Key Takeaways TCO Has Permanently Replaced PPV as the Operating Metric. Purchase Price Variance (PPV) models are inadequate for pharmaceutical
AI in Drug Discovery 2026: What Actually Works, What Remains Hype, and Where the IP Value Sits
The Cost Structure That Makes AI Non-Optional Bringing a New Molecular Entity (NME) to market costs, on average, US $2.8
The Pharmacy of the World at a Crossroads: Navigating Challenges and Embracing a New Era of Global Leadership in Indian Pharma
1. Executive Strategic Overview The Indian pharmaceutical industry, historically celebrated as the “Pharmacy of the World” for its unparalleled capacity
Thinking of signing your company up for DrugPatentWatch?
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find
Thinking of signing your company up for DrugPatentWatch? Read Post »
Generic Drug Market Entry: The Complete Analyst’s Playbook for Patent Cliff Profits
1. The Opportunity in Numbers: Patent Cliff Sizing and Market Structure Global Market Scale and Growth Trajectory The global generic
Generic Drug Market Entry: The Complete Analyst’s Playbook for Patent Cliff Profits Read Post »
How to FOIA an IND Application: The Complete Pharma Intelligence Playbook
For IP teams, portfolio managers, competitive intelligence leads, and institutional investors who need to know what the FDA is holding
How to FOIA an IND Application: The Complete Pharma Intelligence Playbook Read Post »
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors operating in or entering the Russian market. 1. Why
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook Read Post »
